Linkages Between Anxiety and Outcomes in Heart Failure by De Jong, Marla J et al.
University of Pennsylvania
ScholarlyCommons
School of Nursing Departmental Papers School of Nursing
10-2011
Linkages Between Anxiety and Outcomes in Heart
Failure




University of Pennsylvania, briegel@nursing.upenn.edu
Mary Kay Rayens
See next page for additional authors
Follow this and additional works at: http://repository.upenn.edu/nrs
Part of the Behavior and Behavior Mechanisms Commons, and the Cardiology Commons
This paper is posted at ScholarlyCommons. http://repository.upenn.edu/nrs/50
For more information, please contact repository@pobox.upenn.edu.
Recommended Citation
De Jong, M. J., Chung, M. L., Wu, J., Riegel, B., Rayens, M., & Moser, D. K. (2011). Linkages Between Anxiety and Outcomes in Heart
Failure. Heart & Lung: The Journal of Acute and Critical Care, 40 (5), 393-404. http://dx.doi.org/10.1016/j.hrtlng.2011.02.002
Linkages Between Anxiety and Outcomes in Heart Failure
Abstract
Objective
We investigated the relationship between anxiety and event-free survival (ie, composite endpoint of death,
emergency department visits, or hospitalizations) for patients with heart failure (HF), and examined whether
behavioral and physiologic mechanisms mediate any association between anxiety and outcomes.
Methods
In this longitudinal study, patients with HF completed the anxiety subscale of the Brief Symptom Inventory,
and heart-rate variability and plasma norepinephrine levels were measured. Dietary adherence and medication
adherence were measured according to 24-hour urine sodium level and the Medication Event Monitoring
System, respectively. Patients were followed at least 1 year for event-free survival.
Results
In total, 147 patients were enrolled. Patients with high anxiety had a shorter (hazard ratio, 2.2; 95%
confidence interval, 1.1-4.3; P = .03) period of event-free survival than patients with lower anxiety. Anxiety
independently predicted adherence to medication (P = .008), which in turn predicted event-free survival
(hazard ratio, 2.0; 95% confidence interval, 1.2-3.3; P = .008). The effect of anxiety (P = .17) on event-free
survival was less significant when the regression model included both anxiety and adherence to medication
than when the model only included anxiety (P = .03), indicating that adherence to medication mediated the
relationship between anxiety and event-free survival.
Conclusion
This is the first study to show that nonadherence to medication links anxiety and event-free survival for
patients with HF. Interventions that reduce anxiety and improve adherence may benefit outcomes.
Keywords
heart failure, anxiety, adherence, event-free survival
Disciplines
Behavior and Behavior Mechanisms | Cardiology
Author(s)
Marla J. De Jong, Misook L. Chung, Jia-Rong Wu, Barbara Riegel, Mary Kay Rayens, and Debra K. Moser
This journal article is available at ScholarlyCommons: http://repository.upenn.edu/nrs/50
Linkages Between Anxiety and Outcomes in Heart Failure
Marla J. De Jong, PhD, RN, CCNS,
Executive Director, TriService Nursing Research Program, Uniformed Services University of the
Health Sciences
Misook L. Chung, PhD, RN[Associate Professor],
College of Nursing, University of Kentucky
Jia-Rong Wu, PhD, RN[Post-Doctoral Fellow],
College of Nursing, University of Kentucky
Barbara Riegel, DNSc, RN[Professor],
University of Pennsylvania, Philadelphia
Mary Kay Rayens, PhD[Professor], and
College of Nursing, University of Kentucky
Debra K. Moser, DNSc, RN
Professor and Gill Endowed Chair, Co-Director, RICH Heart Program, Director, Center for
Biobehavioral Research in Self-Management, College of Nursing, University of Kentucky
Abstract
OBJECTIVE—To investigate the relationship between anxiety and event-free survival (i.e.,
composite endpoint of death, emergency department visits, or hospitalizations) for patients with
HF, and examine whether behavioral and physiologic mechanisms mediate any association
between anxiety and outcomes.
METHODS—In this longitudinal study, patients with HF completed the anxiety subscale of the
Brief Symptom Inventory, and heart rate variability and plasma norepinephrine level were
measured. Dietary and medication adherence were measured with a 24-hour urine sodium level
and the Medication Event Monitoring System, respectively. Patients were followed at least 1 year
for event-free survival.
RESULTS—A total of 147 patients were enrolled. Patients with high anxiety had a shorter (HR
2.2, 95% CI 1.1–4.3, P = .03) period of event-free survival than patients with lower anxiety.
Anxiety independently predicted medication adherence (P = .008), which in turn predicted event-
free survival (HR 2.0, CI 1.2–3.3, P = .008). The effect of anxiety (P = .17) on event-free survival
was less significant when the regression model included both anxiety and medication adherence
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than when the model only included anxiety (P = .03), indicating that medication adherence
mediated the relationship between anxiety and event-free survival.
CONCLUSION—This is the first study to show that medication nonadherence links anxiety and
event-free survival for patients with HF. Interventions that reduce anxiety and improve adherence
may favorably benefit outcomes.
Over 5,700,000 Americans have heart failure (HF), a chronic condition that contributes to
more than 292,000 deaths annually.1 The effects of demographic, clinical, and treatment
characteristics on outcomes has been well-studied. Improved outcomes have been associated
with use of angiotensin-converting enzyme (ACE) inhibitors,2 beta-adrenergic blockers,3
angiotensin receptor blockers,4 aldosterone inhibitors,5 mechanical circulatory support
devices,6 ventricular reconstruction surgery,7 cardiac resynchronization therapy,8 nutritional
therapy,9 and disease management.10 Nonetheless, HF hospitalizations continue to rise.11
Patients with cardiac disease, including HF, often experience high levels of anxiety.12–17
Anxiety has been linked to adverse outcomes for patients with acute myocardial infarction
(AMI) 18,19 but the link between anxiety and outcomes has not been well-established in
HF.20 Although the mechanisms whereby anxiety may be associated with cardiac outcomes
are unclear,13 evidence suggests that behavioral and physiologic pathways (Figure 1) may
link anxiety and adverse outcomes.13
One physiologic model accounts for the relationships between psychological factors and
heart disease outcomes.21 According to the model, psychological factors, such as anxiety,
stimulate sympathetic nervous system (SNS) activity and catecholamine release that, in
time, produce harmful consequences. Elevated levels of plasma norepinephrine, the standard
biochemical method of assessing severity of SNS activation, predict mortality for patients
with HF.22 For patients with AMI, but not healthy persons, elevated plasma norepinephrine
levels were positively correlated with anxiety.23 Others demonstrated that although patients
with HF had higher baseline sympathetic activity and heart rates than healthy persons, HF
patients had still higher sympathetic activity and heart rates during mental stress, which is
considered an anxiety equivalent.24 Controlling for physiologic variables, anxious patients
with AMI had lower baroreflex cardiac control than nonanxious patients, placing them at
increased risk for dysrhythmias.25 Further, it is well-known that patients with HF have
reduced heart rate variability (HRV)26 due, in part, to high sympathetic activity.27
Depressed HRV independently predicts morbidity and mortality for patients with HF.28
Others have hypothesized that behavioral mechanisms, such as treatment nonadherence, link
anxiety and cardiac disease. Compared to nonanxious persons, those with high anxiety may
eat an unhealthy diet, smoke, consume drugs or alcohol, fail to adhere to therapy, or be
physically inactive.19,29,30 Anxious patients with AMI experience problems coping with
challenges, which may adversely affect treatment adherence and rehabilitation efforts.31
Nonetheless, no investigators have directly examined the hypothesized links of anxiety, SNS
arousal, and poor treatment adherence with clinical outcomes for patients with HF.
The purposes of this study were to investigate the relationship between anxiety and event-
free survival for patients with HF and examine whether behavioral and/or physiologic
mechanisms mediate any association between anxiety and outcomes. We hypothesized that
1) HF patients with high anxiety would have worse event-free survival than patients with
low anxiety and 2) SNS arousal and nonadherence to prescribed treatments would mediate
the association between anxiety and event-free survival.
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MATERIALS AND METHODS
Design
This sub-study was planned a priori as part of a prospective study to assess the relationship
between depression and outcomes for patients with HF. The Institutional Review Board
approved the study and all subjects gave written informed consent.
Sample and setting
Adult outpatients from a university-based medical center and its clinics and a private
hospital located in the midwestern United States were recruited for the study. Providers
referred patients to the researchers, and the researchers posted signs and fliers about the
study in outpatient clinics. Patients were eligible to enroll if they had a confirmed diagnosis
of chronic HF as confirmed by a physician using established criteria widely used by
researchers.32,33 In addition, all eligible patients had undergone evaluation of HF, were on
stable doses of drug therapy, had not been referred for urgent heart transplantation, and read
and spoke English. Patients were excluded if they had: 1) HF due to valvular heart disease,
myocarditis or other inflammatory processes, or pregnancy, 2) a history of cerebral vascular
accident within the past 3 months or chronic major sequelae such as inability to
communicate or persistent hemiplegia or paraplegia, 3) an AMI infarction within the past 3
months, 4) coexisting terminal illness, 5) a major psychiatric disorder, such as
schizophrenia, diagnosed by a clinician and that interfered with the patient’s ability to
answer questions, engage in a longitudinal study, or care for oneself, and 6) impaired
cognition. Patients with symptoms of depression or anxiety were not excluded.
Measures
Anxiety—Anxiety was assessed using the anxiety subscale of the Brief Symptom Inventory
(BSI).34 The 6–item anxiety subscale includes brief descriptions of psychological symptoms
that are associated with anxiety. Using a 0 (“not at all”) to 4 (“extremely”) scale, participants
rate their level of distress concerning these symptoms. The six items are averaged. The
averaged score quantifies the patient’s level of anxiety and can range from 0 to 4. Higher
scores denote higher anxiety. The normative value for healthy adults is 0.35 ± 0.45;
however, normative data are unavailable for patients with HF or other cardiac disorders.34
The subscale contains no physiologic indices of anxiety, such as heart rate or diaphoresis,
that could spuriously overestimate measurement of anxiety in patients with physical disease.
Evidence supporting the validity of each subscale of the BSI has been reported.34
Investigators have reported Cronbach’s α ranging from .85 to .90 when studying patients
with cardiac disease.18,35,36 In this study, the Cronbach α coefficient for the BSI was 0.85.
SNS arousal—Heart rate variability is a noninvasive measure of autonomic nervous
system tone. Patients with HF typically exhibit decreased HRV related to high levels of
sympathetic activity and decreased parasympathetic activity.27,37 Heart rate variability was
measured in the time and frequency domains,38 and assessed from data obtained from 3-
channel 2-hour Holter (Del Mar DigiCorder 483) electrocardiogram (ECG) recordings. A 2-
hour recording period is long enough to accurately measure and assess HRV.39 The
recordings were scanned in semi-automatic mode (operator verification of all beat types) on
a Del Mar 373 Holter Analysis System Scanner (Del Mar Avionics, Irvine, CA). The data
from these recordings included time of beat, type of beat, serial RR intervals (also termed
normal-to-normal [NN] intervals) in milliseconds (ms), and standard deviation of normal
sinus RR intervals in 5-minute epochs for the 2-hour recording period. To demonstrate inter-
and intra-rater reliability, two members of the study team reviewed the recordings and
scanned them twice. The members achieved identical findings for 90% of the recordings.
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When results differed, the members rescanned the recordings to review and resolve areas of
disagreement.
Time-domain analyses are statistical calculations of RR intervals. Time-domain measures
included standard deviation of all NN intervals for a selected time period (SDNN) and
square root of the mean squared differences of successive NN intervals (RMSSD).38
For frequency-domain (or spectral) analysis, fast Fourier transformation was used to
apportion the HRV signal into its frequency components and to quantify the power of these
components.38 Two frequency bands are of clinical interest: 1) low frequency (LF) band
(0.04– 0.15 Hz), and 2) high frequency band (0.15–0.4 Hz).38 In humans, LF and high
frequency peak frequencies are commonly centered around about 0.1 Hz and 0.25 Hz,
respectively. The area under the curve of each frequency band represents the power within
that band. Total power represents the variability of the entire signal and is obtained by
summing the powers of each frequency band. Low frequency and high frequency power also
were “normalized” (i.e., expressed as a percentage of total power).38 Reliability and validity
of this method for reflecting autonomic nervous system tone in cardiac patients have been
demonstrated.38 To perform frequency-domain analysis, the recording period was divided
into consecutive 5-minute epochs.38 An instantaneous HR function was sampled at 256-ms
intervals and smoothed using a 584-ms boxcar filter.40 When artifact or any non-normal
complex occurred, the preceding and succeeding RR intervals were excluded from the
analysis and the instantaneous HR function was estimated by linear interpolation.38 The
entire 5-minute segment was excluded from analysis if more than 95% of the RR intervals
were not NN intervals. The mean NN interval was subtracted from the sampled HR data and
a Hanning window applied.40 A fast Fourier transform was then computed, resulting in an
absolute 5-minute power spectrum.
Plasma norepinephrine, a second measure of SNS arousal used in this study, is a standard
biochemical method of assessing severity of SNS activation, and has been shown to predict
mortality in HF.22 To ensure valid measurement, the blood sample was obtained under the
following conditions to control for factors that extraneously affect norepinephrine release: 1)
blood was drawn through a catheter that was placed at least 30 minutes prior to sampling in
order to avoid pain and anxiety associated with venipuncture, 2) patients remained in the
same semi-fowlers position for 30 minutes prior to the blood draw, 3) patients were asked to
refrain from caffeine, alcohol, and nicotine for at least 8 hours prior to data collection, 4) the
room was comfortably warm and quiet with minimal interruptions, and 5) data collection
was conducted at the same time of day (1300–1500).41 Blood was collected into centrifuge
blood tubes containing ethylenediaminetetraacetic acid (an anticoagulant), immediately
placed on ice, and centrifuged at 4°C. Specimens were stored in single-use aliquots at
−80°C until time of analysis. Plasma concentrations were determined using the Bi-Cat
ELISA kit (American Laboratory Products Company, Windham, NH). Mean intra- and
inter-assay coefficients of variation for the laboratory were < 8%, indicating reproducible
and valid measurement.
Adherence—Objective evidence of dietary adherence was measured using 24-hour urine
sodium levels. Patients were given urinals, urine collection hats, and urine jugs as well as
written and oral instructions regarding how to collect urine for 24 hours. Patients were
instructed to record the time and amount of each void in a urination log. Either a member of
the research team visited the patient’s home to pick up the 24-hour urine collection, or the
patient returned the collection to a member of the research team, usually in conjunction with
another appointment. In either case, the team member reviewed the urine log for
completeness with the patient.
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A 2–3 gram sodium diet is recommended for patients with mild HF.42 Dietary sodium is
absorbed and subsequently secreted. Urinary sodium represents approximately 86%43 to
95%44 of sodium intake depending primarily on amount of perspiration. Most patients with
HF do not engage in strenuous physical activity that produces significant perspiration;
therefore, urinary sodium represents approximately 95% of sodium intake. Thus, a urinary
sodium of 2.85 grams (123 mmol), which is 95% of 3 grams, was used to define adherence
to a sodium restricted diet.
Objective evidence of medication adherence was measured using the Medication Event
Monitoring System (MEMS). The MEMS (AARDEX, Union City, CA) is a microelectronic
device housed within the cap of a medication vial. The MEMS records the date and time that
the patient removes the cap from the medication vial and presumably takes the correct dose
of the medication. To ensure accuracy, patients documented in a diary additional cap
removals related to medication refills or other openings not associated with intake of the
medication. The MEMS collects real-time data which are later downloaded to a computer.
Evidence supporting the validity of the MEMS to assess HF patients’ adherence with
prescribed medications has been reported.45–47 In fact, use of an electronic monitoring
device is now the preferred standard method to assess adherence.48 Data were collected for
one HF medication (ACE inhibitor, diuretic, beta-adrenergic blocker, digoxin) for each
patient. The medication selected for MEMS monitoring was one that the patient took twice
per day. If all medications were taken once daily, however, the MEMS was used for the
beta-adrenergic blocker. If no beta-adrenergic blocker was prescribed, the MEMS was used
for the ACE inhibitor or angiotensin receptor blocker. Patients used the MEMS for 3 months
and were unable to access data stored within the MEMS. We defined medication adherence
as the percent of days correct doses taken ([total number of days dose taken/total number of
days prescribed] × 100). Acceptable adherence was defined as equal to or greater than 88%
because Wu and colleagues reported that this level of adherence was most sensitive and
specific in predicting event-free survival.49
Procedure
Initial data collection occurred at a research center. Sociodemographic (i.e., age, education
level, gender, ethnicity, marital status,) and clinical characteristics (i.e., left ventricular
ejection fraction, comorbidities, smoking status, beta-adrenergic blocker use, ACE inhibitor
use, New York Heart Association [NYHA] functional class) data were collected by patient
interview and medical record review. Patients completed the BSI Anxiety Subscale and
questionnaires regarding demographic information. Next, patients were placed in a semi-
fowlers position, a saline-filled butterfly access device was inserted, cardiac leads were
placed on the patient’s chest, and 2-hour Holter monitoring began. After 30 minutes, a
plasma norepinephrine blood sample was drawn. The patient was given written and verbal
instructions for how to collect 24-hour urine specimen and use the MEMS medication vial.
Patients were given a urine collection set and arrangements were made to obtain the urine
specimen.
Three-month data collection—Three months after initial data collection, the patient
returned the MEMS device by giving it to a study team member during a home visit,
delivering it during a regularly scheduled clinic visit, or mailing it in a prepaid package.
Company-provided equipment was used to download MEMS data to a personal computer.
12-month data collection—Twelve months after initial data collection, a study team
member reviewed patients’ medical records, the hospital administrative record database,
death certificates, and patient diaries, and also interviewed patients and family members to
collect data about rehospitalizations, emergency department (ED) visits, and mortality.
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Patients were followed until 12-month data collection was accomplished for all subjects.
Thus, some patients were followed longer than 12 months. The reliability and validity of
outcome measures were determined by having all investigators examine the same record and
comparing their conclusions. In addition, the accuracy of classifying events was ensured by
using multiple methods to determine whether and when an event occurred.
Data analysis
Data were analyzed with SPSS software, version 16.0 (SPSS Inc., Chicago, IL). For all
analyses, a P value of ≤ .05 was considered statistically significant. To test the first
hypothesis, patients were divided into quartile groups based on their BSI anxiety score.
Because these anxiety groups may have differed on some demographic and clinical
characteristics that needed to be controlled for statistically, baseline differences were
examined using either ANOVA or linear by linear association chi-square tests (for
dependent nominal variables), as appropriate. Cox proportional hazard modeling was used to
assess whether anxiety predicted event-free survival, while controlling for the potential
covariates of age, gender, left ventricular ejection fraction, NYHA classification, ACE
inhibitor use, and beta-adrenergic blocker use.
For the second hypothesis, a series of regression models was used to determine whether SNS
arousal and/or adherence to prescribed treatments mediated any relationship between high
anxiety and event-free survival. Mediation was considered to have occurred if there was a
significant relationship between anxiety and event-free survival that became nonsignificant
when the mediator was included in the model. The test for mediation followed the steps
outlined by Baron and Kenny.50 In summary, the initial step tested whether anxiety
predicted event-free survival, as described above to test the first hypothesis. The second step
tested whether anxiety predicted each potential mediator (i.e., dietary adherence and
medication adherence) using multiple regression. The next step tested whether the mediators
predicted event-free survival (using Cox regression), and finally whether anxiety and the
potential mediator variables predicted event-free survival when entered together into the
model. Mediation is present if, in the final regression, a mediator predicted the outcome and
the P value testing the relationship between anxiety and outcomes was less significant than
the P value in the first step.
RESULTS
Characteristics of the sample
Characteristics of the sample are summarized in Table 1. The average age of the 147
participants was 61 ± 11 years and nearly one-third were women (30%). Over half the
participants were married (61%) and the majority was Caucasian (88%).
Anxiety and event-free survival
The mean anxiety score was 0.71 ± 0.74, and 79 (54.1%) patients reported higher anxiety
than the norm reference of 0.35 for healthy adults. Based on the distribution of anxiety
scores, the subjects were stratified into four groups (Table 2), from lowest anxiety to highest
anxiety, to facilitate Cox proportional hazard modeling. The four groups are not strict
quartiles because 30% of the patients reported no anxiety. There were no differences in
sociodemographic or clinical variables among the four anxiety groups.
The mean follow-up time to first event was 389 ± 324 days. The first event outcomes shown
in Table 3 were used for event-free survival analyses. The data confirmed the first
hypothesis. Cox proportional hazard modeling revealed that after adjusting for age, gender,
NYHA class, left ventricular ejection fraction, ACE inhibitor use, and beta-adrenergic
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blocker use, high anxiety independently predicted event-free survival (Figure 2, Table 4).
Patients in the highest anxiety group were more likely to visit the ED, be hospitalized, or die
compared to those in the three lower anxiety groups (HR 2.2, 95% CI 1.1–4.3, P = .03).
SNS arousal as mediator
The mean plasma norepinephrine level was .36 ± .23 nmol/L. Norepinephrine level was not
related to anxiety, adherence, or all measures of HRV except SDNN (Table 5).
Heart rate variability monitoring was conducted for 65 subjects but contraindicated for the
remaining subjects, who had atrial fibrillation or paced cardiac rhythms. As expected, the
distribution of LF and high frequency power was positively skewed; therefore, these values
were log transformed from the 0.04–0.15 Hz and 0.15–0.4 Hz frequency bands, respectively.
The time-domain and frequency-domain measurements of HRV are shown in Table 6. No
measures of HRV, except SDNN as mentioned above, were correlated with anxiety,
adherence, or norepinephrine level (Table 5).
Given the lack of association between both anxiety and plasma norepinephrine level, and
anxiety and HRV (Table 5), the data did not support the hypothesis that SNS arousal
mediates the association between anxiety and event-free survival.
Nonadherence as mediator
Urinary sodium levels from the 24-hour urine specimen were 196.27 ± 92.26 mmol/day,
which computes to an average daily sodium intake of 4512.18 ± 2121.11 mg/day. Of the 141
patients (95.9%) with a useable 24-hour urine sample, 24% had a computed sodium intake
of ≤ 3 gms. There was no association between anxiety and dietary adherence, as measured
by the 24-urine sodium level (Table 5), thus, we did not use dietary adherence in any further
mediation tests.
MEMS data were available for 135 patients (91.8%). Subjects used the MEMS for one of
their prescribed medications for an average of 94 ± 18 days. Based on date and time data
from the MEMS, patients took the correct number of doses on 80.6% ± 22.8% days.
Individually, 56% of patients took the correct number of doses on ≥ 88% of the days that
they used the MEMS. Medication adherence was correlated with anxiety (Table 5).
The data regarding objectively-measured medication adherence demonstrated that
medication adherence mediated the relationship between anxiety and event-free survival,
thus partially supporting the second hypothesis. To demonstrate a mediation effect of
medication adherence, it is first necessary for anxiety to predict event-free survival. This
was evident in the Cox regression reported above and shown in Figure 2. Further
demonstration of mediation requires evidence that anxiety predict medication adherence.
The regression analysis reported in Table 7 demonstrates this relationship. It is then
necessary to demonstrate a relationship between medication adherence and event-free
survival. Figure 3 shows that after adjusting for age, gender, NYHA class, left ventricular
ejection fraction, ACE inhibitors, and beta-adrenergic blockers, medication adherence
independently predicted, event-free survival (P = 0.001). Patients who took the correct
number of doses on less than 88% of days were twice (CI 1.2–3.3, P = .008) as likely to
experience the combined endpoint. The final step in demonstrating mediation is to show, in
a regression that includes both anxiety and medication adherence, that the effect of anxiety
on event-free survival has an associated P value that is higher (less significant) than the P
value for the relationship between anxiety and event-free survival when anxiety is entered as
a predictor without adherence. Table 4 and Table 8 show that medication adherence
mediated the relationship between anxiety and poorer HF outcomes because the effect of
anxiety on event-free survival was less significant (P = .17) when the regression model
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included both anxiety and medication adherence than when the model only included anxiety
(P = .03).
DISCUSSION
To our knowledge, this is the first study to show that anxiety predicts event-free survival for
patients with HF, and that medication adherence behavior mediates this relationship. The
findings are unique because, unlike others,51,52 we found that high anxiety independently
predicted clinical outcomes. Although anxiety has been shown to contribute to poor
outcomes for patients with other cardiovascular disorders,18,19 this new evidence shows that
high anxiety and nonadherence to prescribed medications helps explain untoward outcomes
for patients with HF that cannot be fully accounted for by sociodemographic or clinical
variables. These data indicate that it is critical for clinicians to assess anxiety in all patients
with HF.
These results align with past findings which indicated that patients with HF have high levels
of anxiety. In fact, patients with HF have been shown to be more anxious than patients with
other cardiac disorders.53,54 Sources of anxiety for patients with HF may include
progressive and debilitating physical symptoms with poor long-term prognosis; complex
medication, dietary, and activity treatment regimens; comorbidities, recurring
hospitalization, hopelessness and loss of control, failure of usual coping mechanisms,
isolation from family and friends, frustrations with a complicated healthcare system,
financial worries, and fear of death.
The rates of nonadherence to prescribed medications for patients in this study, consistent
with previous research reports,55,56 reveals that individual patient adherence remains
problematic. Measured objectively for 3 months, only 56% of patients took the correct
number of medication doses on 88% or more of the days that they used the MEMS. Anxiety
predicted medication adherence. Nonadherence may be related to disagreements about the
treatment regimen, side effects of medications, complex dosing schedules, multiple
medications, concerns about medication effectiveness, improved symptoms, attitude about
the importance of the medication, cost, and self-care deficit, all of which may be associated
with anxiety.57,58 Although the exact mechanism by which anxiety is related to adherence
remains unknown, anxiety may impair cognition, learning, energy, motivation, and patients’
willingness and ability to adhere to treatment.31 Further research is needed to elucidate how
anxiety, a complex and distressing emotion with psychological, physiological, behavioral,
and cognitive manifestations impacts adherence to medications or other interventions that
are commonly prescribed for patients with HF.
The objective measure of dietary adherence, the 24-hour urine sodium level, did not predict
outcomes or mediate the relationship between anxiety and outcomes. This may be because
we measured urine sodium level once. In contrast, we measured medication adherence for 3
months.
Unlike others, we found no relationship between anxiety and measures of SNS arousal.
Likewise, HRV arousal did not predict outcomes, likely due to the small number of patients
eligible for HRV monitoring. In addition, most patients in this study were prescribed beta-
adrenergic blockers and ACE inhibitors, which have been shown to affect HRV and perhaps
diminish ANS and neurohormonal disturbances.59,60 Although beta-adrenergic blockers
have been shown to affect HRV,60 we enrolled patients who took these medications because
beta-adrenergic blockers are the standard of care for patients with HF.42,61 Researchers have
been criticized for enrolling patients who are not representative of the typical patient with a
given condition.62 Thus, to avoid this shortfall, which would diminish our ability to
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generalize findings to the typical patient with HF, we enrolled patients who took beta-
adrenergic blockers. In addition, it would have been unethical to discontinue these therapies,
and difficult to enroll sufficient numbers of patients who, for whatever reason, do not take
these medications.
Practice guidelines for the management of HF mention the importance of medication
adherence but ignore the assessment and management of anxiety, and do not include
detailed recommendations for how to improve medication adherence.42 Hundreds of clinical
trials have been conducted to test interventions designed to improve adherence for patients
with cardiovascular or other chronic disorders. In summary, physician-supervised, nurse-
mediated, home-based management strategies; patient education and discharge planning;
reminder cards, calls or alarms; medication container design, improved patient
communication with clinicians, improved dosing schedules, extended clinic hours,
prescription of once-daily formulations or “polypills,” positive reinforcement, electronic
monitoring systems, social support, and patient-centered medication instructions have been
shown to improve medication adherence and/or outcomes.58,63–65 Patients in a previous
study who are married were more likely to be adherent than patients without a spouse,
indicating that interventions designed to improve adherence should include the patient’s
spouse.66 Where the guidelines fall short, however, is that, at best, they encourage clinicians
to consider the patient’s psychologic state when deciding how to educate and manage
patients. Absent are recommendations to assess anxiety or initiate interventions to reduce
anxiety. Similarly, recently published review and clinical papers contain a plethora of
strategies that clinicians can use to improve adherence but omit mention of anxiety.57,58,67
Importantly, our findings indicate anxiety predicts medication adherence, which in turn
mediates the relationship between high anxiety and worse outcomes.
LIMITATIONS
Four limitations of this study have the greatest impact on the findings. First, more subjects
than expected had atrial fibrillation or paced cardiac rhythm, preventing HRV analysis for
these subjects. Second, we used the documented admission diagnosis in each subject’s
medical record for first event outcomes. We did not anticipate a large number of nonspecific
diagnoses, such as edema and shortness of breath, that were consistent with a HF diagnosis
but not documented as such. As a result, we classified more subjects than expected as “other
hospitalization.” Third, the sample size was small but nevertheless adequate to demonstrate
a relationship between anxiety and event-free survival. We recommend that future
investigators conduct a larger study to confirm or refute our findings and to test the best
strategies to improve adherence. Fourth, although the ethnicity of the sample reflects the
patient population where the study was conducted, the sample lacks racial diversity.
CONCLUSIONS
We found that anxiety predicted event-free survival for patients with HF, and that
medication adherence mediated this relationship. Although causality cannot be inferred from
our data, the results of this study suggest that it may be important for clinicians to
objectively assess medication adherence for patients with HF, and to consider customizing
interventions according to patient needs and preferences. Assessment of medication
adherence should be included in clinical practice guidelines for management of patients with
HF. Nearly all patients used the MEMS without difficulty and were accepting of it. It may
not be feasible or cost-effective for clinicians to objectively assess medication adherence for
all patients. Nonetheless, our findings indicate that clinicians are obligated to pay special
attention to medication adherence, especially for highly anxious patients and those who
frequently require hospitalization or visit the ED. If nonadherence is suspected, the MEMS
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is an attractive assessment method. Further, the approximate $100 cost of the MEMS is
justified if nonadherence is corrected and hospitalization or ED visits are avoided.
In summary, the mediation effect of nonadherence to prescribed medications on the
relationship between anxiety and outcomes adds to the body of research. The astute
assessment of anxiety and medication adherence merit increased attention from clinicians
who manage patients with HF because medication adherence helps explain how anxiety is
associated with adverse outcomes. Although we did not conduct a randomized trial to test
intervention strategies for patients with differing levels of anxiety, findings from this study
indicate a need for such research, particularly for patients with the highest levels of anxiety.
Interventions designed to reduce anxiety and improve adherence to prescribed medications
may improve outcomes.
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Fig 1.
Proposed physiologic and behavioral pathways linking anxiety and adverse outcomes
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Fig 2.
Cox survival plot of anxiety by quartile and event-free survival
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Fig 3.
Cox survival plot of medication adherence and event-free survival
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TABLE I
Sample demographic and clinical characteristics (N = 147)
Characteristic
Age (yrs) 61 ± 11
Education (yrs) 13 ± 3
Women, n (%) 44 (30)
Ethnicity
   Caucasian, n (%) 130 (88)
   Black, n (%) 16 (11)
   Hispanic or Latino, n (%) 1 (1)
Marital status
   Married/cohabitate, n (%) 90 (61)
   Widowed, n (%) 24 (16)
   Divorced/separated, n (%) 19 (13)
   Single, n (%) 14 (10)
Left ventricular ejection fraction (%) 35 ± 14
Prior acute myocardial infarction, n (%) 85 (58)
Prior coronary artery bypass grafting, n (%) 51 (35)
Prior hypertension, n (%) 113 (77)
History of diabetes, n (%) 70 (48)
Current smoker, n (%) 28 (19)
Prescribed beta-adrenergic blocker, n (%) 131 (89)
Prescribed angiotensin-converting enzyme inhibitor, n (%) 106 (72)
New York Heart Association classification
   I, n (%) 9 (6)
   II, n (%) 47 (32)
   III, n (%) 65 (44)
   IV, n (%) 22 (15)
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TABLE II
Mean anxiety score by quartile
Group N Mean BSI Score
Lowest quartile (0–30%) 43 0.00 ± 0.00
Second quartile (31–50%) 31 0.30 ± 0.13
Third quartile (51–75%) 33 0.84 ± 0.13
Highest quartile (76–100%) 39 1.73 ± 0.51
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TABLE III
First event outcomes at the follow-up point
Outcome N (%)
Heart failure death 2 (1.4)
Other death 1 (0.7)
Heart failure hospitalization 10 (6.8)
Cardiac disease hospitalization 23 (15.6)
Other hospitalization 29 (19.7)
Heart failure emergency department visit 2 (1.4)
Cardiac disease emergency department visit 4 (2.7)
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TABLE IV
Adjusted hazard ratios for the prediction of event-free survival from anxiety controlling for age, gender,







Age 1.015 .991–1.039 .22
Gender .851 .490–1.480 .57
Prescribed angiotensin-converting enzyme inhibitor .626 .351–1.118 .11
Prescribed beta-adrenergic blocker .472 .218–1.022 .06
Left ventricular ejection fraction .987 .968–1.007 .22
New York Heart Association classification 1.2 .712–2.023 .49
Second anxiety quartile* 1.146 .523–2.511 .73
Third anxiety quartile* .814 .383–1.729 .59
Fourth anxiety quartile* 2.167 1.091–4.304 .03
*
Compared to lowest quartile of anxiety
Omnibus test of model coefficients χ2 = 23.79, P = .005
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TABLE V
Correlations between anxiety level, plasma norepinephrine level, dietary adherence, medication adherence,








Anxiety level (n =
146) ------------ .04; p = .67 .18; p =.04 −.10; p = .26
Dietary adherence
(n = 141) .04; p = .67 ------------ −.15; p = .11 −.05; p = .57
Medication




−.10; p = .26 −.05; p = .57 −.01; p = .96 ------------
SDNN (n = 65) −.13; p = .30 −.01; p = .97 −.17; p = .22 −.26; p = .03
RMSSD (n = 65) −.21; p = .08 −.17; p = .18 .08; p = .56 −.08; p = .50
LF nu (n = 65) .10; p = .41 .15; p = .26 −.22; p = .12 .07; p = .61
HF nu (n = 65) −.10; p = .41 −.15; p = .26 .22; p = .12 −.07; p = .61
Log LF (n = 65) .09; p = .49 .15; p = .25 −.14; p = .30 −.17; p = .18
Log HF (n = 65) −.003; p = .98 .06; p = .64 −.01; p = .95 −.20; p = .12
Log LF/HF ratio (n
= 65) .15; p = .24 .15; p = .25 −.21; p = .13 .01; p = .95
A
Measured at the continuous level
B
Reflected by 24 hour urine sodium excretion
C
Adherence as the percent of days correct doses taken
D
Measured at the continuous level
LF = low frequency; HF = high frequency; nu = normalized units; RMSSD = square root of the mean squared differences of successive NN
intervals; SDNN = standard deviation of all NN intervals
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TABLE VI
Mean time-domain and frequency-domain measurements of heart rate variability (N = 65)
Time-Domain
   SDNN (ms) 56 ± 26
   RMSSD (ms) 32 ± 20
Frequency-Domain
   LF 248.9 ± 392.1
   HF 241.4 ± 339.5
   LF nu 49.8 ± 21.1
   HF nu 50.2 ± 21.1
   Log LF 4.6 ± 1.4
   Log HF 4.9 ± 1.2
   Log LF/HF ratio 1.0 ± 0.2
LF = low frequency; HF = high frequency; nu = normalized units; RMSSD = square root of the mean squared differences of successive NN
intervals; SDNN = standard deviation of all NN intervals
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TABLE VIII
Adjusted hazard ratios for the prediction of event-free survival from anxiety and medication adherence








Age 1.007 .982–1.032 .60
Gender .902 .487–1.670 .74
Prescribed angiotensin-converting enzyme inhibitor .538 .293–.988 .05
Prescribed beta-adrenergic blocker .442 .181–1.078 .07
Left ventricular ejection fraction .988 .966–1.010 .29
New York Heart Association classification 1.141 .632–2.050 .66
Second anxiety quartile* .884 .336–2.321 .80
Third anxiety quartile* .952 .413–2.194 .91
Fourth anxiety quartile* 1.682 .795–3.560 .17
Medication adherence 1.345 1.060–1.708 .02
*
Compared to lowest quartile of anxiety
Omnibus test of model coefficients χ2 = 29.73, P = .001
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